Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.798
Buy
RSI(14)
70.441
Buy
STOCH(KDJ)(9,3,3)
88.973
Overbought
ATR(14)
0.889
High Vlolatility
CCI(14)
139.500
Buy
Williams %R
5.306
Overbought
TRIX(12,20)
0.379
Sell
StochRSI(14)
77.210
Neutral
10X Genomics Inc
TXG20.460USD
+1.170+6.07%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.59BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of 10X Genomics Inc
Currency: USD Updated: 2026-01-09Key Insights
10X Genomics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 34 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 17.27.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
10X Genomics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
10X Genomics Inc Highlights
StrengthsRisks
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.28% year-on-year.
Undervalued
The company’s latest PE is -32.81, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 126.11M shares, decreasing 11.01% quarter-over-quarter.
Held by HOTCHKIS & WILEY
Star Investor HOTCHKIS & WILEY holds 2.42K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.35.
Analyst Rating
Based on
18
analysts
Hold
Current Rating
17.267
Target Price
-5.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-09The current financial score of 10X Genomics Inc is 7.60, ranking 69 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 149.00M, representing a year-over-year decrease of 1.75%, while its net profit experienced a year-over-year decrease of 23.16%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
5.17
Operational Efficiency
9.45
Growth Potential
6.22
Shareholder Returns
7.17
10X Genomics Inc's Company Valuation
Currency: USD Updated: 2026-01-09The current valuation score of 10X Genomics Inc is 8.21, ranking 39 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -32.81, which is -83.18% below the recent high of -5.52 and -28.96% above the recent low of -42.31.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 34/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-09The current earnings forecast score of 10X Genomics Inc is 6.89, ranking 160 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 16.00, with a high of 20.00 and a low of 14.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
18
analysts
Hold
Current Rating
17.267
Target Price
-5.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
113
Total
6
Median
9
Average
Company name
Ratings
Analysts
10X Genomics Inc
TXG
18
Medtronic PLC
MDT
33
Stryker Corp
SYK
32
Dexcom Inc
DXCM
31
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
29
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-09The current price momentum score of 10X Genomics Inc is 9.06, ranking 39 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 22.39 and the support level at 16.85, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
19.474
Buy
MA10
17.923
Buy
MA20
17.032
Buy
MA50
16.643
Buy
MA100
14.753
Buy
MA200
12.586
Buy
Institutional Confidence
Currency: USD Updated: 2026-01-09The current institutional shareholding score of 10X Genomics Inc is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 108.27%, representing a quarter-over-quarter increase of 5.68%. The largest institutional shareholder is The Vanguard, holding a total of 13.25M shares, representing 11.38% of shares outstanding, with 13.92% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
Millennium Management LLC
Sumitomo Mitsui Trust Bank, Limited
Amova Asset Management Co., Ltd.
Wellington Management Company, LLP
Quantinno Capital Management LP
BofA Global Research (US)
1
2
Risk Assessment
Currency: USD Updated: 2026-01-09The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 10X Genomics Inc is 4.85, ranking 94 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 2.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.24
VaR
+6.71%
240-Day Maximum Drawdown
+52.65%
240-Day Volatility
+73.32%
Return
Best Daily Return
60 days
+17.31%
120 days
+17.31%
5 years
+24.37%
Worst Daily Return
60 days
-6.53%
120 days
-8.23%
5 years
-24.70%
Sharpe Ratio
60 days
+3.36
120 days
+1.88
5 years
-0.30
Risk Assessment
Maximum Drawdown
240 days
+52.65%
3 years
+88.66%
5 years
+96.47%
Return-to-Drawdown Ratio
240 days
+0.72
3 years
-0.21
5 years
-0.18
Skewness
240 days
+0.61
3 years
+0.09
5 years
+0.19
Volatility
Realised Volatility
240 days
+73.32%
5 years
+69.62%
Standardised True Range
240 days
+3.82%
5 years
+15.05%
Downside Risk-Adjusted Return
120 days
+461.86%
240 days
+461.86%
Maximum Daily Upside Volatility
60 days
+66.80%
Maximum Daily Downside Volatility
60 days
+41.32%
Liquidity
Average Turnover Rate
60 days
+2.90%
120 days
+2.91%
5 years
--
Turnover Deviation
20 days
+34.84%
60 days
+60.44%
120 days
+61.05%
Peer Comparison
Healthcare Equipment & Supplies
10X Genomics Inc
TXG
7.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
BSX
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
BDX
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of 10X Genomics Inc?
The TradingKey Stock Score provides a comprehensive assessment of 10X Genomics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of 10X Genomics Inc’s performance and outlook.
How do we generate the financial health score of 10X Genomics Inc?
To generate the financial health score of 10X Genomics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects 10X Genomics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of 10X Genomics Inc.
How do we generate the company valuation score of 10X Genomics Inc?
To generate the company valuation score of 10X Genomics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare 10X Genomics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of 10X Genomics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of 10X Genomics Inc.
How do we generate the earnings forecast score of 10X Genomics Inc?
To calculate the earnings forecast score of 10X Genomics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on 10X Genomics Inc’s future.
How do we generate the price momentum score of 10X Genomics Inc?
When generating the price momentum score for 10X Genomics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of 10X Genomics Inc’s prices. A higher score indicates a more stable short-term price trend for 10X Genomics Inc.
How do we generate the institutional confidence score of 10X Genomics Inc?
To generate the institutional confidence score of 10X Genomics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about 10X Genomics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of 10X Genomics Inc.
How do we generate the risk management score of 10X Genomics Inc?
To assess the risk management score of 10X Genomics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of 10X Genomics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of 10X Genomics Inc.
